OMER
OMEROS CORP
NASDAQ · Healthcare · Biotechnology · US
$18.39
−2.96%Oct 16, 2026, 15:26 UTC
OMEROS CORP shares fell 12.61% to $16.42 in U.S. trading.
Source:Oct 16, 2026, 10:19 UTC
The EUROPEAN MEDICINES AGENCY's EUROPEAN MEDICINES AGENCY issued a negative opinion on OMEROS CORP's marketing authorization application for narsoplimab to treat TA-TMA following re-examination.
Sep 22, 2026, 17:51 UTC
In July, the Centers for Medicare & Medicaid Services granted New Technology Add-on Payment status to Omeros Corp's Yartemlea, effective October 1, 2026.
Source:Aug 13, 2026, 01:05 UTC
Omeros reduced its convertible debt after the quarter ended.
Source:Aug 13, 2026, 01:05 UTC
Omeros reported second-quarter net sales of $28.5 million for YARTEMLEA, its newly launched treatment for TA-TMA, and generated positive operating cash flow.
Source:Aug 13, 2026, 00:00 UTC
Omeros Corporation appointed Joseph Schocken as a director, effective August 12, 2026, and granted him a stock option to purchase 30,000 shares of common stock on the date of appointment.
Aug 12, 2026, 20:02 UTC
Omeros Corporation reported financial results for the second quarter ended June 30, 2026, including gross revenues of $32.2 million from YARTEMLEA, its approved treatment for stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
Jun 26, 2026, 18:11 UTC
The European Medicines Agency's expert panel rejected Omeros Corp's primary commercial asset.
Source: